


WO 2005/012305

30

PCT/GB2004/003183


Claims

1. A compound for inhibiting the activity of PARP having formula I:



and pharmaceutically acceptable salts thereof

2. A compound for inhibiting the activity of PARP having formula II:




and pharmaceutically acceptable salts thereof.

WO 2005/012305

31

PCT/GB2004/003183


3. A compound for inhibiting the activity of PARP having formula

**III**

and pharmaceutically acceptable salts thereof.

4. A compound according to claim 1, wherein the compound is in the form of a phosphate salt of the following formula:

Formula I - phosphate




5. The use of a therapeutic amount of a compound of formula I, and pharmaceutically acceptable salts thereof, in the manufacture of a medicament.


WO 2005/012305

PCT/GB2004/003183


32



6. The use of a therapeutic amount of a compound of formula II, and pharmaceutically acceptable salts thereof, in the manufacture of a medicament.



7. The use of a therapeutic amount of a compound of formula III, and pharmaceutically acceptable salts thereof, in the manufacture of a medicament.



8. The use of a therapeutic amount of a compound of formula I, and

pharmaceutically acceptable salts thereof, in the manufacture of a medicament for the treatment of a disease or condition that is caused by a genetic defect in a gene that mediates homologous recombination.

9. The use of a therapeutic amount of a compound of formula II, and pharmaceutically acceptable salts thereof, in the manufacture of a medicament for the treatment of a disease or condition that is caused by a genetic defect in a gene that mediates homologous recombination.
10. The use of a therapeutic amount of a compound of formula III, and pharmaceutically acceptable salts thereof, in the manufacture of a medicament for the treatment of a disease or condition that is caused by a genetic defect in a gene that mediates homologous recombination.
11. The use as claimed in any one of claims 8 to 10, wherein the defect is a gene encoding a protein involved in HR.
12. The use as claimed in any one of claims 8 to 10, wherein the defect is the absence of a gene encoding a protein involved in HR.
13. The use as claimed in any one of claims 8 to 10, wherein the defect is in the expression of a gene encoding a protein involved in HR.

WO 2005/012305

PCT/GB2004/003183

34

14. The use of a therapeutically effective amount of a compound of formula I and pharmaceutically acceptable salts thereof, in the manufacture of a medicament for inducing apoptosis in HR defective cells.
15. The use of a therapeutically effective amount of a compound of formula II, and pharmaceutically acceptable salts thereof, in the manufacture of a medicament for inducing apoptosis in the defective cells.
16. The use of a therapeutically effective amount of a compound of formula III, and pharmaceutically acceptable salts thereof, in the manufacture of a medicament for inducing apoptosis in the defective cells.
17. The use of a therapeutically effective amount of a compound of formula I, and pharmaceutically acceptable salts thereof, in the manufacture of a medicament for the treatment of cancer.
18. The use of a therapeutically effective amount of a compound of formula II, and pharmaceutically acceptable salts thereof, in the manufacture of a medicament for the treatment of cancer.
19. The use of a therapeutically effective amount of a compound of formula III, and pharmaceutically acceptable salts thereof, in the manufacture of a medicament for the treatment of cancer.

20. The use of a compound according to any one of claims 15 to 17, wherein the cancer is gene-linked hereditary cancer.
21. The use of a therapeutically effective amount of a compound of formula I, and pharmaceutically acceptable salts thereof, in the manufacture of a medicament for the treatment of cancer cells defective in BRCA1 and/or BRCA2 expression.
22. The use of a therapeutically effective amount of a compound of formula II, and pharmaceutically acceptable salts thereof, in the manufacture of a medicament for the treatment of cancer cells defective in BRCA1 and/or BRCA2 expression.
23. The use of a therapeutically effective amount of a compound of formula III, and pharmaceutically acceptable salts thereof, in the manufacture of a medicament for the treatment of cancer cells defective in BRCA1 and/or BRCA2 expression.
24. The use of a compound according to any one of claims 21 to 23, wherein the cancer cells to be treated are partially or totally deficient in BRCA1 and/or BRCA2 expression.
25. A pharmaceutical composition comprising a compound of formula I, and a pharmaceutically acceptable salt thereof, as an active ingredient.
26. A pharmaceutical composition comprising a compound of formula II, a pharmaceutically acceptable salt thereof, as an active ingredient.

27. A pharmaceutical composition comprising a compound of formula III and a pharmaceutically acceptable salt thereof, as an active ingredient.
28. A pharmaceutical composition according to any one of claims 25 to 27, wherein the composition further comprises at least one diluent and/or carrier together with at least one bulking agent.
29. A pharmaceutical composition according to claim 28, wherein the carrier and/or diluent is selected from any of the following either alone or in combination, saline, buffered saline, dextrose, water, glycerol and ethanol.
30. A method for the treatment of cancer in mammals comprising administering a compound of formula I as described in claim 1; or a pharmaceutically acceptable salt thereof:
31. A method for the treatment of cancer in mammals comprising administering a compound of formula II as described in claim 2, or a pharmaceutically acceptable salt thereof:
32. A method for the treatment of cancer in mammals comprising administering a compound of formula III as described in claim 3, or a pharmaceutically acceptable salt thereof: